| [1] |
Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development[J]. Trends Cancer, 2024, 10(7): 627-642. DOI: 10.1016/j.trecan.2024.03.008.
pmid: 38600020
|
| [2] |
Stroobant EE, Strong VE. Advances in gastric cancer surgical management[J]. Hematol Oncol Clin North Am, 2024, 38(3): 547-557. DOI: 10.1016/j.hoc.2024.01.003.
|
| [3] |
Kim SE, Park MI, Lee MH. Chemotherapy for metastatic gastric cancer[J]. Korean J Gastroenterol, 2025, 85(1): 1-10. DOI: 10.4166/kjg.2024.139.
|
| [4] |
Alkhathami AG, Pallathadka H, Shah S, et al. LncRNAs in modula-ting cancer cell resistance to paclitaxel (PTX) therapy[J]. Med Oncol, 2024, 42(1): 28. DOI: 10.1007/s12032-024-02577-1.
pmid: 39671022
|
| [5] |
Alkhathami AG, Pallathadka H, Shah S, et al. Mechanisms behind the lncRNAs-mediated regulation of paclitaxel (PTX) resistance in human malignancies[J]. Exp Cell Res, 2025, 445(2): 114434. DOI: 10.1016/j.yexcr.2025.114434.
|
| [6] |
Coan M, Haefliger S, Ounzain S, et al. Targeting and engineering long non-coding RNAs for cancer therapy[J]. Nat Rev Genet, 2024, 25(8): 578-595. DOI: 10.1038/s41576-024-00693-2.
|
| [7] |
Modabber N, Mahboub SS, Khoshravesh S, et al. Evaluation of long non-coding RNA (lncRNA) in the pathogenesis of chemotherapy resistance in cervical cancer: diagnostic and prognostic approach[J]. Mol Biotechnol, 2024, 66(10): 2751-2768. DOI: 10.1007/s12033-023-00909-6.
|
| [8] |
He Z, Wang J, Zhu C, et al. Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis[J]. Cancer Lett, 2022, 548: 215751. DOI: 10.1016/j.canlet.2022.215751.
|
| [9] |
Xia Z, Zhang L, Zhou H, et al. LncRNA-FGD5-AS1 promotes 5-Fu resistance of cervical cancer cells through modulating the miR-130a-3p-YTHDF2 axis[J]. J Chemother, 2025, 37(8): 710-722. DOI: 10.1080/1120009X.2024.2436803.
|
| [10] |
Qin S, Liu Y, Zhang X, et al. lncRNA FGD5-AS1 is required for gastric cancer proliferation by inhibiting cell senescence and ROS production via stabilizing YBX1[J]. J Exp Clin Cancer Res, 2024, 43(1): 188. DOI: 10.1186/s13046-024-03103-x.
pmid: 38965605
|
| [11] |
Hao M, Li T, Xiao L, et al. METTL3-induced FGD5-AS1 contri-butes to the tumorigenesis and PD-1/PD-L1 checkpoint to enhance the resistance to paclitaxel of endometrial carcinoma[J]. J Cell Mol Med, 2024, 28(5): e17971. DOI: 10.1111/jcmm.17971.
|
| [12] |
Fei D, Yuan H, Zhao M, et al. LncRNA FGD5-AS1 potentiates autophagy-associated doxorubicin resistance by regulating the miR-154-5p/WNT5A axis in osteosarcoma[J]. Cell Biol Int, 2022, 46(11): 1937-1946. DOI: 10.1002/cbin.11889.
|
| [13] |
Amioka A, Kadoya T, Sueoka S, et al. Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer[J]. Breast Cancer, 2021, 28(5): 1062-1071. DOI: 10.1007/s12282-021-01241-0.
pmid: 34047951
|
| [14] |
Harada K, Sakamoto N, Kitaoka T, et al. PI3 expression predicts recurrence after chemotherapy with DNA-damaging drugs in gastric cancer[J]. J Pathol, 2025, 265(4): 472-485. DOI: 10.1002/path.6400.
|
| [15] |
Xu J, Xu Y, Ye G, et al. LncRNA-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis[J]. J Chemother, 2023, 35(6): 527-538. DOI: 10.1080/1120009X.2022.2157618.
|
| [16] |
Naseri B, Farsad-Akhtar N, Mardi A, et al. lncRNA PVT1 silencing inhibits gastric cancer cells' progression via enhancing chemosensitivity to paclitaxel[J]. Gene, 2025, 932: 148900. DOI: 10.1016/j.gene.2024.148900.
|
| [17] |
Tong KH, Qian J. Long non-coding RNA FGD5-AS1 is an inducer of cisplatin chemoresistance in gastric cancer cells by sponging miR-195[J]. J Biol Regul Homeost Agents, 2021, 35(2): 819-826. DOI: 10.23812/20-667-L.
|
| [18] |
Brandl A, Prabhu A. Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens[J]. J Gastrointest Oncol, 2021, 12(Suppl 1): S32-S44. DOI: 10.21037/jgo-2020-04.
pmid: 33968424
|
| [19] |
Ye M, Xiu LJ, Ji QQ, et al. Research progress in targeted therapies for gastric cancer[J]. Int J Clin Pharmacol Ther, 2022, 60(12): 509-514. DOI: 10.5414/CP204250.
|
| [20] |
Usman RM, Razzaq F, Akbar A, et al. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance[J]. Asia Pac J Clin Oncol, 2021, 17(3): 193-208. DOI: 10.1111/ajco.13449.
|
| [21] |
Shetty A, Venkatesh T, Kabbekodu SP, et al. LncRNA-miRNA-mRNA regulatory axes in endometrial cancer: a comprehensive overview[J]. Arch Gynecol Obstet, 2022, 306(5): 1431-1447. DOI: 10.1007/s00404-022-06423-5.
|
| [22] |
Patel D, Thankachan S, Sreeram S, et al. LncRNA-miRNA-mRNA regulatory axes as potential biomarkers in cervical cancer: a comprehensive overview[J]. Mol Biol Rep, 2025, 52(1): 110. DOI: 10.1007/s11033-024-10215-2.
|